Entecavir – CRI Report

Investigation Report on China Entecavir Market 2020-2024

admin — Wed, 30 Sep 2020 05:19:59 +0000

Description
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China by the end of 2019, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B every year, causing a loss of over CNY100 billion for society.
Entecavir, a drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth greatly.
According to CRI’s market research, the annual sales value of entecavir in China rose from CNY1126 million in 2013 to CNY 1996 million in 2017 and decreased to CNY1264 in 2019. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 40% in 2019 by sales value.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape.
According to CRI, Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales volume will keep growing in the next few years. However, due to the decline in average prices, sales of entecavir in the Chinese market may continue to decline.

Topic covered
-sales value and volume of entecavir in China 2015-2019
– sales value and volume of entecavir by dosages in China 2015-2019
-competitive landscape of entecavir in Chinese market
-price of entecavir by regions in China
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China

The post Investigation Report on China Entecavir Market 2020-2024 first appeared on CRI Report.

Sample of Investigation Report on China’s Entecavir Market, 2018-2022

admin — Wed, 13 Mar 2019 08:06:07 +0000

This is a free sample of the report

Investigation Report on China’s Entecavir Market, 2018-2022

The post Sample of Investigation Report on China’s Entecavir Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Entecavir Market, 2018-2022

admin — Wed, 02 Jan 2019 02:36:16 +0000

Description
In China, more than 100 billion people are chronically infected with hepatitis B virus (HBV), of which 20 million to 30 million have chronic hepatitis B. It is estimated that every year, more than 500,000 people in China die of the liver damage or liver cancer caused by chronic hepatitis B, which leads to losses of over CNY 100 billion.
Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth. In Mar. 2005, Entecavir was approved by the FDA. Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir was launched in China at the beginning of 2006 after being approved by the China Food and Drug Administration (CFDA) at the end of 2005. Later, Chinese pharmaceutical companies launched generic Entecavir successively, which drove the growth of the market.
According to CRI’s market research, the annual sales value of Entecavir increased from over CNY 30 million in 2006 to CNY 2.03 billion in 2016, and decreased slightly in 2017. Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir still dominates the market. Its market share by sales value reached about 40% in 2017 but is shrinking as impacted by China-made generic drugs.
Entecavir has better and faster antiviral effect and see less side effects and drug resistance than traditional nucleoside analogs. Having a high genetic barrier to resistance, it is a powerful and long-acting HBV inhibitor for early monotherapy. As the demand for new anti-HBV drugs is far from being met, China’s Entecavir market is promising with rising sales value in the coming years.

Topics Covered:
– Development environment of China’s Entecavir market
– Size of China’s Entecavir market
– Competitive landscape of China’s Entecavir market
– Prices of Entecavir in China
– Major factors influencing the development of China’s Entecavir market
– Prospect of China’s Entecavir market

The post Investigation Report on China’s Entecavir Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China Entecavir 2018-2022

admin — Thu, 01 Nov 2018 06:25:06 +0000

Description
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI’s market survey, the annual sales value of entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Topics covered
-market size of entecavir in China
-competitive landscape of entecavir in Chinese market
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China

The post Investigation Report on China Entecavir 2018-2022 first appeared on CRI Report.